Atezolizumab plus bevacizumab for patients with Child-Pugh-B in hepatocellular carcinoma

作     者：Shinji Itoh Masafumi Ikeda 

作者机构：Department of Surgery and ScienceGraduate School of Medical SciencesKyushu UniversityFukuokaJapan Department of Hepatobiliary and Pancreatic OncologyNational Cancer Center Hospital EastKashiwaJapan 

出 版 物：《Hepatobiliary Surgery and Nutrition》 (肝胆外科与营养（英文）)

年 卷 期：2022年第11卷第6期

页      面：876-878页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：ICMJE 

主　　题：bevacizumab hepatocellular patients 

摘      要：Atezolizumab plus bevacizumab is currently the main choice of first-line treatment for unresectable hepatocellular carcinoma(HCC),which has been proven superior to sorafenib for overall survival(OS)and progression-free survival(PFS)in the phase III IMbrave150 trial(1).Up-data analysis from IMbrave150 showed that the median OS was 19.2 months for atezolizumab plus bevacizumab and 13.4 months for sorafenib[hazard ratio(HR)=0.66;95%confidence interval(CI):0.52-0.85;P=0.0009],and the median PFS was 6.9 and 4.3 months(HR=0.65;95%CI:0.53-0.81;P=0.0001)(2).